Innovent Biologics was among the investors in the oncology therapy developer’s oversubscribed round, which came as global investors are boosting their healthtech, biotech and wellness investment activities in China despite the country’s trade war with the US.
China-headquartered cancer therapeutics developer AnHeart Therapeutics has secured $61m in series B funding featuring biological drug group Innovent Biologics, the latest deal in a booming Chinese biopharmaceutical technology investment space.
Healthcare-focused investment manager Octagon Capital Advisors led the round, which included Cenova, Laurion Capital and Sage Partners, taking AnHeart’s overall funding to $100m since it was founded in 2018.
AnHeart is developing clinical-stage precision oncology therapies for difficult-to-treat cancers. The company is headquartered in the southern Chinese city of Hangzhou,…
